Fig 1.
Summary of specimens and data flow in InterMEL.
Table 1.
Demographic, clinical, and detailed pathologic characteristics for patients and melanomas at the time of initial diagnosis (total, n = 561*).
Table 2.
Assessment of target FFPE tissue areas for extractions of nucleic acids from tumor and non-tumor specimens.
Table 3.
Characteristics of RNA and DNA obtained from tumor and non-tumor tissues.
Fig 2.
Effect of melanoma characteristics and time elapsed between tissue sectioning and co-extraction, on the quantity and quality of DNA/RNA.
Fig 3.
Effect of case and tumor characteristics, and time elapsed between sectioning and co-extraction on the core’s DNA-QC score.
Fig 4.
Biospecimens received, processed, and distributed for testing.
Table 4.
Characteristics of participants and their melanomas for cases and controls with available full histopathology review and with samples allocated for testing, by miRNA, methylation, and mutation profiling platforms.
Fig 5.
Effect of case, tumor, DNA characteristics, and logistics, on the success of methylation screening.